1% over 5 years the 95% CI is

from 689 to 2127, representing the NNH for the upper (RR=2.45) and lower (RR=1.47) ranges of the 95% confidence interval for the relative rate of MI for patients on abacavir reported by the D:A:D study, respectively. To determine how different risk components contribute to the change in the underlying risk of MI and NNH variability, we performed a series of analyses using different risk assumptions over two different time periods (Table 1), choosing a patient profile that reflects D:A:D patients’ characteristics as described in the Methods section: male, aged 40 years, nonsmoking with no diagnosis of diabetes, no changes in electrocardiogram (ECG), an sBP of 120 mmHg, a total cholesterol value of 170 mg/dL (4.4 mmol/L) and an HDL cholesterol value of 60 mg/dL (1.5 mmol/L). The NNH drops from 1111 to 555 for such a patient Bortezomib solubility dmso when the

patient is diagnosed with diabetes, and by the same amount when the patient develops hypercholesterolaemia (total cholesterol value of 240 mg/dL; 6.2 mmol/L) or left ventricular hypertrophy is present on ECG. The NNH drops further to 370 if the patient’s sBP increases to 160 mmHg or his HDL cholesterol value decreases to 35 mg/dL (0.9 mmol/L) and to 277 Veliparib concentration if the patient starts smoking. When two risk components with unfavourable levels coexist at the same time and in the same patient, the NNH drops from 1111 to around 100 for most pairs of risk factors, except smoking combined with unfavourable HDL cholesterol, for which the NNH decreases even further to 69. The NNH decreases to 7 when all risk factors are defined as unfavourable at the same time and the underlying 5-year risk of an MI is 15%. The NNH was further calculated after adjusting for the presence of a history of CVD, as defined in the Methods nearly section, and was found to drop from 1111 to 22 and from 370 to 11, for 5- and 10-year risks of MI, respectively. Figure 2 presents a series of graphs relating NNH to any possible age and sBP, and categorizes it according to smoking status and two chosen lipid profiles. In these graphs it is also

possible to observe the change in NNH while different risk components are modified separately or consecutively. These graphs illustrate the impact on NNH of the introduction of an additional risk factor, here smoking and unfavourable lipid profile. Comparison of graphs A and B demonstrates that smoking produces a marked decrease in NNH, which means that you would need to treat considerably fewer smokers to observe one additional MI, and comparison of graphs C and D demonstrates that a further decrease in NNH is seen with an additional risk of an unfavourable lipid profile. To give a specific example, a 50-year-old, nonsmoking patient with favourable lipid profiles and sBP of 120 mmHg will have an NNH in the range of 200–500 (graph A), while a patient of the same age who smokes (but who also has favourable lipid profiles and sBP of 120 mmHg) will have an NNH in the range of 50–100 (graph B).